Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Equity Ratio (2020 - 2025)

Historic Equity Ratio for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to 0.77.

  • Barinthus Biotherapeutics' Equity Ratio fell 837.04% to 0.77 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.77, marking a year-over-year decrease of 837.04%. This contributed to the annual value of 0.81 for FY2024, which is 688.99% down from last year.
  • Latest data reveals that Barinthus Biotherapeutics reported Equity Ratio of 0.77 as of Q3 2025, which was down 837.04% from 0.79 recorded in Q2 2025.
  • Barinthus Biotherapeutics' 5-year Equity Ratio high stood at 0.96 for Q2 2021, and its period low was 0.32 during Q1 2021.
  • Moreover, its 5-year median value for Equity Ratio was 0.87 (2023), whereas its average is 0.8.
  • Its Equity Ratio has fluctuated over the past 5 years, first surged by 37880.77% in 2022, then crashed by 837.04% in 2025.
  • Quarter analysis of 5 years shows Barinthus Biotherapeutics' Equity Ratio stood at 0.9 in 2021, then grew by 0.04% to 0.9 in 2022, then decreased by 3.15% to 0.87 in 2023, then dropped by 6.89% to 0.81 in 2024, then fell by 4.6% to 0.77 in 2025.
  • Its Equity Ratio was 0.77 in Q3 2025, compared to 0.79 in Q2 2025 and 0.81 in Q1 2025.